RFK Jr.'s HHS Opens Peptide Compounding; Hims Jumped 6% as Critics Warn of Risks
Pharmacies can compound BPC-157, TB-500 and four other peptides under conditions, with FDA rulemaking still pending and public comments due Nov. 13.
The Department of Health and Human Services said Oct. 28 that it will use "enforcement discretion" for compounding pharmacies that make six peptides FDA has not yet added to its compounding list, Health Secretary Robert F. Kennedy Jr. announced. Hims & Hers ($HIMS) rose 6% that day, according to TIKR. HIMS traded at $20.10, down 3.41%, at 10:44 a.m. ET Thursday.
What HHS did
- Six peptides. The policy covers BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, each in a specified form and route, according to law firm Venable.
- Who is covered. State-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A. Outsourcing facilities under section 503B are not covered.
- Conditions. Compounders must use a bulk substance from an FDA-registered manufacturer with a certificate of analysis, report adverse events to FDA's MedWatch and states, use a single active ingredient and a "not for resale" label, and use only an FDA-cleared syringe.
- Interim and non-binding. The policy, published in the Federal Register on Oct. 30, lasts until a final rule decides whether each peptide goes on the 503A list. It does not add them to that list. Comments are due Nov. 13 on Docket HHS-OASH-2026-0496.
How it got here
| Date | Event |
|---|---|
| Feb. 27 | Kennedy tells Joe Rogan he is a "big fan" of peptides |
| Apr. 15 | Kennedy says FDA will take several peptides out of its significant-risk category; Hims rose about 14% |
| July | FDA advisory committee votes to back listing the six peptides |
| Oct. 28 | HHS announces enforcement discretion for the six |
| Oct. 30 | Policy published in the Federal Register |
| Nov. 13 | Public comment period closes |
Hims & Hers
- Peptide plans. CEO Andrew Dudum said in August, per Reuters as cited by TIKR, that Hims is waiting for final FDA rulemaking before selling peptides still under review. TIKR said Hims plans to offer NAD+, sermorelin and glutathione by year-end under existing compounding pathways.
- Q3 results. Hims reported Nov. 9 that Q3 revenue rose 49% to $890.4M and that it posted a $33.0M net loss, versus net income of $15.8M a year earlier. It lowered full-year adjusted EBITDA guidance to $257M–$277M.
The safety debate
- AMA. The American Medical Association says many newer injectable peptides lack the evidence needed to judge their safety. It warns that gray-market products may be contaminated or differ from what is advertised, and advises patients to talk to a physician first.
- FDA staff. FDA's drug center recommended against listing each of the six peptides, and HHS departs from that advice, according to Venable.
- Advisory panel. The Alliance for Safe Biologic Medicines asked HHS on Oct. 26 to pause the policy. It noted that eight panelists Kennedy added were the only votes in favor of BPC-157, KPV and TB-500, each by an 8-6 margin, Becker's Hospital Review reported.
- Other critics. The Center for Science in the Public Interest argued in JAMA that listing would undermine the drug-approval process, and Public Citizen urged HHS to rescind the policy.
What to watch
- Nov. 13 comment deadline. Public comments on the interim policy close Friday.
- FDA rulemaking. Whether FDA proposes adding some or all of the six peptides to the 503A list. HHS said it may revisit the policy if a safety signal or quality problem emerges.
- Hims' offerings. Which peptide products the company decides to sell, and when.
This article is informational only and is not investment advice.
Readers also read
AMD, Broadcom Rise as Nvidia CEO's Exit Rattles AI Trade; CoreWeave, Nebius Slide
NewsNasdaq Jumps 2.2% as CoreWeave Revives the AI Trade; Microsoft Falls 2.2%
NewsCoreWeave CEO Says Data Center Backlash Won't Slow Buildout as Shares Rebound
NewsWall Street Downgrades Nvidia: Bernstein, Evercore, Oppenheimer Cut Ratings as Targets Fall
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.
